Emerging Roles of Epigenetic Regulators in Inflammatory Diseases
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 190
Special Issue Editors
2. Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo University, Ningbo 315211, China
3. Key Laboratory of Applied Marine Biotechnology of Ministry of Education, Ningbo University, Ningbo 315211, China
Interests: drug discovery; inhibitors; epigenetic regulation; protein-protein interaction; metal complex inhibitors; kinase inhibitors; demthylase inhibitors; innate immunity
Special Issues, Collections and Topics in MDPI journals
Interests: anti-tumor discovery and development from Traditional Chinese Medicine; tumor immunology and tumor environment; natural product in senescence treatment
Special Issues, Collections and Topics in MDPI journals
Interests: neuroinflammation; neuro-oncology; neurodegeneration; epigenetics; histone modifications; signal transduction; transcription factors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Emerging evidence suggests that epigenetic events play a crucial role in the initiation and progression of inflammation by influencing various immune components, including cytokines, complements, antimicrobial peptides, cancer-related genes and other inflammation-related genes. These epigenetic modifications can lead to the aberrant activation or suppression of genes in both immune and non-immune cells under inflammatory conditions, contributing to the development of inflammatory diseases such as atherosclerosis, sepsis, diabetes, autoimmune disorders, neurodegenerative diseases and cancer. Although it is well-established that immune responses can induce epigenetic changes during the genesis and progression of inflammatory diseases, the specific contribution of the immune component versus the stimulated host cell in driving these epigenetic modifications remains unclear. Furthermore, while some epigenetic alterations have been extensively characterized, their underlying mechanisms and origins are still not fully understood.
The aim of the Special Issue is to provide a comprehensive overview of the recent advancements and emerging research related to the involvement of epigenetic regulators in various inflammatory diseases and their potential as therapeutic targets. The scope of this Special Issue encompasses, but is not limited to, the following:
(1) Epigenetic modifications in inflammatory disease;
(2) Identification and characterization of epigenetic markers that can serve as diagnostic, prognostic or predictive tools for various diseases;
(3) Novel insights into the development and application of epigenetic-based therapies, including small-molecule inhibitors, epigenetic editing tools and gene-targeting strategies, to modulate aberrant epigenetic regulation in diseases;
(4) Investigation of the underlying molecular mechanisms by which epigenetic regulators, such as DNA methylation, histone modifications, chromatin remodeling and non-coding RNAs, influence gene expression and cellular functions in disease contexts;
(5) Discussions on the translation of epigenetic research findings into clinical applications, including challenges, limitations and future directions for the development of epigenetic-based therapies and personalized medicine approaches.
Through this Special Issue, we aim to provide researchers and clinicians a platform to share cutting-edge research, foster interdisciplinary collaborations and promote a deeper understanding of the emerging roles of epigenetic regulators in inflammatory disease pathogenesis and therapeutic interventions.
You may choose our Joint Special Issue in Life.
Dr. Guanjun Yang
Dr. Renyikun Yuan
Prof. Dr. Christina Piperi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- histone modifications
- microRNAs
- LncRNAs
- DNA methylation
- epigenetic regulation
- inhibitors or agonists
- inflammatory diseases
